Takiguchi M, Murakami M, Nakagawa I, Rashid M M, Tosa N, Chikuma S, Hashimoto A, Uede T
Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
J Vet Med Sci. 2000 Jan;62(1):29-36. doi: 10.1292/jvms.62.29.
MRL/lpr mouse is an established animal model which develops autoimmune diseases including glomerulonephritis, sialoadenitis, hepatitis and inflammatory lung disease. Additionally, it has been reported that lpr strains uniquely accumulate CD3+ CD4- CD8- B220+ (double negative, DN) T cells in lymphoid organs leading to lymphadenopathy and splenomegaly. To investigate the role of CD28/CTLA4-B7 pathway in the development of lymphadenopathy and splenomegaly, MRL/lpr mice were treated with soluble form of CTLA4 molecules, CTLA4IgG, which efficiently blocks this pathway. It was demonstrated that (i) the development of DN T cells was independent of the CD28/CTLA4-B7 pathway, (ii) the CD28/CTLA4-B7 pathway was required for the development of lymphadenopathy and splenomegaly, (iii) the CD28/CTLA4-B7 pathway was important for the accumulation of various cell populations in the lymph node and spleen, (iv) composition of the accumulating cell populations was not altered by CTLA4IgG treatment, and (v) activation of conventional T cells and IL-4 production from conventional T cells were the CD28/CTLA4-B7 pathway dependent. Thus, we concluded that the CD28/CTLA4-B7 pathway was required for the development of full-blown lymphadenopathy and splenomegaly in MRL/lpr mice.
MRL/lpr小鼠是一种已确立的动物模型,会发展出自身免疫性疾病,包括肾小球肾炎、涎腺炎、肝炎和炎症性肺病。此外,有报道称,lpr品系在淋巴器官中独特地积累CD3+CD4-CD8-B220+(双阴性,DN)T细胞,导致淋巴结病和脾肿大。为了研究CD28/CTLA4-B7通路在淋巴结病和脾肿大发展中的作用,用CTLA4分子的可溶性形式CTLA4IgG处理MRL/lpr小鼠,CTLA4IgG可有效阻断该通路。结果表明:(i)DN T细胞的发育独立于CD28/CTLA4-B7通路;(ii)CD28/CTLA4-B7通路是淋巴结病和脾肿大发展所必需的;(iii)CD28/CTLA4-B7通路对淋巴结和脾脏中各种细胞群的积累很重要;(iv)CTLA4IgG处理不会改变积累细胞群的组成;(v)传统T细胞的激活和传统T细胞产生IL-4依赖于CD28/CTLA4-B7通路。因此,我们得出结论,CD28/CTLA4-B7通路是MRL/lpr小鼠发生全面淋巴结病和脾肿大所必需的。